Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
Metrics to compare | ORY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipORYPeersSector | |
---|---|---|---|---|
P/E Ratio | −21.4x | −3.1x | −0.6x | |
PEG Ratio | −6.27 | −0.01 | 0.00 | |
Price/Book | 1.1x | 3.6x | 2.6x | |
Price / LTM Sales | 6.2x | 19.1x | 3.1x | |
Upside (Analyst Target) | 204.1% | 157.6% | 55.4% | |
Fair Value Upside | Unlock | 14.8% | 10.2% | Unlock |